Pharmaceuticals

Scilex sets a date to pay out Semnur stock to its shareholders. We dig into whether this is a true value unlock or a move born from financial pressure.

New data showing a 300% spike in demand for Burmese prescription translations is a stark economic signal of a deeper demographic shift challenging U.S. healthcare.

As the deadly Bundibugyo Ebola strain spreads with no approved vaccine, a small pharma company is positioning its cancer drug as a potential broad-spectrum shield.

Teva's new Eylea biosimilar hits Europe, a key move in its 'Pivot to Growth' strategy that promises to shake up the lucrative ophthalmology market.

A key regulatory win in Japan propels a potential first-ever treatment for Netherton Syndrome, but the real story is the high-wire act of global commercialization.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

A first-in-class drug aims to calm overactive immune cells, offering a new blueprint for treating diseases like rheumatoid arthritis. But can it deliver?

SciSparc's subsidiary just spent nearly C$10M on a quantum computing firm. This is the operational innovation designed to fix billion-dollar clinical trial failures.

With a 'best-in-class' obesity drug and a novel MASH therapy, clinical-stage MetaVia is set to woo investors. Can its science stand out against the giants?

With an FDA decision just weeks away, Ionis's olezarsen could redefine care for a debilitating condition, marking a pivotal moment for RNA-targeted medicine.

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.

A new collaborative funding model is accelerating a revolutionary approach to ALS treatment, targeting the disease's core mechanism. Here's the why behind the buy.

A global giant's acquisition of a niche Irish recycler reveals the high-stakes consolidation of the invisible networks powering the circular economy.

With its world-first gastric cancer drug heading for approval, Innovent Biologics isn't just offering new hope—it's executing a masterclass in strategic leverage.

Beyond dividends, Stevanato Group's recent shareholder meeting signals a deeper shift in corporate governance, modernizing for stability and trust.

As Alkermes prepares for a key investor conference, it's not just about numbers. It's about a bold new strategy in sleep medicine, a billion-dollar pipeline, and a new CEO.

As CEO Reshma Kewalramani takes the stage, investors will look for clues on how Vertex plans to pivot from CF dominance to a multi-franchise powerhouse.

ADC Therapeutics' lymphoma drug ZYNLONTA shows promise in a Phase 3 trial, but a concerning safety signal in older patients complicates its path to market.

With a new CEO known for scaling software firms, STARLIMS is betting big on agentic AI and M&A to dominate the mission-critical lab informatics market.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.